What is the recommended management of urinary tract infection in pediatric patients, including empiric antibiotic selection, dosing, duration, and considerations for age, renal function, and drug allergies?

Management of Pediatric Urinary Tract Infections

For uncomplicated cystitis in children, treat with nitrofurantoin for 5 days or TMP/SMX for 3 days; for febrile UTI/pyelonephritis, use oral ceftriaxone, cefpodoxime, or ciprofloxacin (if local resistance <10%) for 5-7 days, with initial IV ceftriaxone reserved for those requiring hospitalization. 1

Empiric Antibiotic Selection

Uncomplicated Cystitis

• First-line: Nitrofurantoin (5 days) is the preferred agent as it spares broader-spectrum antibiotics for other infections 1
• Alternative: TMP/SMX (3 days) if local resistance rates are acceptable 1
• Duration: 3-5 days is appropriate for uncomplicated cystitis 2

Febrile UTI/Pyelonephritis (Outpatient)

The choice depends critically on local resistance patterns:

Oral regimens 1, 3:

• Ciprofloxacin 500-750 mg twice daily for 7 days (only if fluoroquinolone resistance <10%)
• Levofloxacin 750 mg daily for 5 days
• Cefpodoxime 200 mg twice daily for 10 days
• Ceftibuten 400 mg daily for 10 days
• TMP/SMX 160/800 mg twice daily for 14 days (dependent on local resistance)

Critical caveat: If using oral cephalosporins empirically, administer an initial IV dose of ceftriaxone to ensure adequate initial coverage 3

Febrile UTI/Pyelonephritis (Inpatient)

Initial IV therapy 3:

• Preferred: Ceftriaxone 1-2 g daily (recommended for low multidrug resistance risk)
• Ciprofloxacin 400 mg twice daily
• Levofloxacin 750 mg daily
• Gentamicin 5 mg/kg daily or Amikacin 15 mg/kg daily (with or without ampicillin)
• Cefotaxime 2 g three times daily
• Piperacillin/tazobactam 2.5-4.5 g three times daily

Early IV-to-oral transition is strongly supported: Oral therapy is as effective as IV for most children with pyelonephritis who are clinically improving 2. Transition when the child is afebrile, tolerating oral intake, and showing clinical improvement.

Complicated UTI Management

Complicated UTI encompasses a heterogeneous population including children with anatomical/functional abnormalities, recurrent infections, severe presentation, immunosuppression, or neonates 4.

Key Differences from Uncomplicated UTI

• Broader pathogen spectrum: E. coli remains predominant, but Pseudomonas aeruginosa and other organisms are more common 5
• Higher resistance rates: ESBL-producing organisms comprise 23% of enterobacteria in complicated cases 5
• Risk factors for MDR: Male sex, previous antibiotic use (therapeutic or prophylactic) in last 3 months 5

Empiric Coverage for Complicated UTI

Antipseudomonal coverage is essential 5:

• Amikacin demonstrated 100% susceptibility and is the most appropriate initial empiric choice 5
• Piperacillin/tazobactam
• Ceftazidime or cefepime
• Carbapenems (reserve for known/suspected ESBL or MDR organisms) 3

Avoid cephalosporins as monotherapy in complicated cases due to inadequate coverage 5

Duration for Complicated UTI

• 7 days for non-bacteremic complicated UTI 1, 6
• 7 days for Gram-negative bacteremia from urinary source 1, 6
• Exception: Men with suspected acute bacterial prostatitis may require 10-14 days 6

Special Population: Neonates and Young Infants (0-90 days)

Empiric Regimen

• Ampicillin PLUS gentamicin or cefotaxime to cover E. coli and Group B Streptococcus 7
• Critical step: Exclude meningitis before shortening IV therapy or transitioning to oral antibiotics, particularly in neonates ≤28 days 7

Duration and Route

• Shorter IV courses are safe after meningitis exclusion, even with bacteremia 7
• IV-to-oral transition with amoxicillin-clavulanate is pharmacokinetically supported in selected term neonates who are clinically improving 7
• Non-carbapenem therapy is appropriate for ESBL UTI without bacteremia in improving infants 7

Age-Specific Considerations

Infants and Young Children

• 5-day oral course is reasonable for uncomplicated febrile UTI with clinical improvement (STOP trial evidence), though SCOUT trial showed borderline noninferiority 2
• Renal ultrasound advised in all young children with first febrile UTI 8
• Treatment within 48 hours of fever onset reduces renal scarring risk 8

Adolescents (≥12 years, ≥40 kg)

• Gepotidacin (approved 2025) is available for uncomplicated UTI in females with resistant infections 2
• Otherwise, follow adult cystitis guidelines

Renal Function Adjustments

• Nitrofurantoin: Can use with CrCl as low as 30 mL/min for 5-day regimens 1
• Aminoglycosides: Dose adjustment required; monitor levels
• Fluoroquinolones: Dose reduction needed for severe renal impairment

Drug Allergy Considerations

• Penicillin allergy: Use fluoroquinolones (if age-appropriate and resistance <10%), or aztreonam for severe reactions
• Sulfa allergy: Avoid TMP/SMX; use nitrofurantoin or beta-lactams
• Multiple allergies: Aminoglycosides remain an option with appropriate monitoring

Common Pitfalls to Avoid

1. Do NOT use nitrofurantoin, oral fosfomycin, or pivmecillinam for pyelonephritis - insufficient efficacy data 3
2. Do NOT treat asymptomatic bacteriuria - high-impact stewardship opportunity 2
3. Do NOT use fluoroquinolones if local resistance >10% 3
4. Do NOT use cephalosporins alone for complicated UTI - inadequate pseudomonal and ESBL coverage 5
5. Do NOT delay meningitis evaluation in neonates before shortening therapy 7
6. Do NOT routinely prescribe prophylaxis after first febrile UTI in children with normal urinary tracts 2

Antibiotic Prophylaxis

Not indicated in children with normal urinary tract following first febrile UTI 2. Reserve for specific high-risk subgroups (recurrent UTI with anatomical abnormalities, high-grade vesicoureteral reflux). When indicated, nitrofurantoin is the preferred prophylactic agent 2.